Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
- PMID: 21452309
- DOI: 10.1002/art.30207
Is there a need for immunopharmacologic guidance of anti-tumor necrosis factor therapies?
Comment on
-
Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study.Arthritis Rheum. 2011 Apr;63(4):877-83. doi: 10.1002/art.30209. Arthritis Rheum. 2011. PMID: 21452312
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources